Danish pharmaceutical conglomerate Novo Nordisk is breaking the trend of recent consolidation in the world’s pharmaceutical industry, reports say, as the company instead is focusing on expanding its research and development staff.
According to reports, the firm holds a dominant market position in the diabetes treatment industry and has cash to spend. But the firm said that while it is eyeing some smaller takeovers, Novo Nordisk sees no significant benefit to major acquisitions across the globe.
The company announced earlier this month it will add 3,000 new employees to its research and development staff in Denmark in the next eight years.
In an interview, Novo Nordisk COO Kare Schultz said that small buyouts could be on the horizon, but the company plans to stick to a 25-year plan to avoid major acquisitions.
”Of course, we could merge with another company given our high value, but we do not see any strategic reason to do so,” Schultz said.
The company is bucking a recent trend of multibillion-dollar mergers in the pharmaceutical industry. According to reports, 2014 has already see 14 pharma mergers with a value of over $1 billion announced.
Full content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Massachusetts AG Sues Insulin Makers and PBMs Over Alleged Price-Fixing Scheme
Jan 14, 2025 by
CPI
Apple and Amazon Avoid Mass Lawsuit in UK Over Alleged Collusion
Jan 14, 2025 by
CPI
Top Agent Network Drops Antitrust Suit Against National Association of Realtors
Jan 14, 2025 by
CPI
Weil, Gotshal & Manges Strengthens Antitrust Practice with New Partner
Jan 14, 2025 by
CPI
Russian Court Imposes Hefty Fine on Google for Non-Compliance with Content Removal Orders
Jan 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand